Glenmark settles drug pricing case with US Department of Justice

US-based Glenmark Pharmaceuticals Inc, a subsidiary of the company, has entered into a three-year deferred prosecution agreement with DOJ involving historical pricing practices by former employees relating to the generic drug pravastatin between 2013 and 2015

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/1Nbf5Ap
via IFTTT